PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
14697904-7	2004	In comparison with milacemide, N,N-bis(carbamoylmethyl)-N-pentylamine was the best and exclusive substrate for MAO-B.	milacemide	19-29	monoamine oxidase B	Homo sapiens	111-116
14697904-8	2004	2-N-(phenylethylamino)-acetoamide was the good substrate for MAO-A and MAO-B same as milacemide.	milacemide	85-95	monoamine oxidase A	Homo sapiens	61-66
14697904-8	2004	2-N-(phenylethylamino)-acetoamide was the good substrate for MAO-A and MAO-B same as milacemide.	milacemide	85-95	monoamine oxidase B	Homo sapiens	71-76
10591050-5	1999	Species differences were also evident in the interactions derivatives of milacemide [2-n-pentylaminoacetamide] as substrates and mechanism-based inhibitors of MAO-B.	milacemide	73-83	monoamine oxidase B	Rattus norvegicus	159-164
10591050-5	1999	Species differences were also evident in the interactions derivatives of milacemide [2-n-pentylaminoacetamide] as substrates and mechanism-based inhibitors of MAO-B.	milacemide	85-109	monoamine oxidase B	Rattus norvegicus	159-164
7646533-0	1995	Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B.	milacemide	62-72	monoamine oxidase B	Rattus norvegicus	97-116
9755023-3	1998	The purpose of this study was: (1) to investigate the effect of the anticonvulsant agent, milacemide, a glycine pro-drug on STR-allodynia; (2) to compare this effect with that of milacemide on normal nociception (without STR); and (3) to determine the sensitivity of the anti-allodynic effect of milacemide to pretreatment with selective monoamine oxidase (MAO)-A (clorgyline) and MAO-B (L-deprenyl) inhibitors.	milacemide	90-100	monoamine oxidase A	Rattus norvegicus	338-363
9755023-3	1998	The purpose of this study was: (1) to investigate the effect of the anticonvulsant agent, milacemide, a glycine pro-drug on STR-allodynia; (2) to compare this effect with that of milacemide on normal nociception (without STR); and (3) to determine the sensitivity of the anti-allodynic effect of milacemide to pretreatment with selective monoamine oxidase (MAO)-A (clorgyline) and MAO-B (L-deprenyl) inhibitors.	milacemide	90-100	monoamine oxidase B	Rattus norvegicus	381-386
7646533-1	1995	Oxidation of the anticonvulsant drug milacemide [2-n-(pentylamino)acetamide] by monoamine oxidase-B (MAO-B) has been reported to be important in terminating its activity.	milacemide	37-47	monoamine oxidase B	Rattus norvegicus	80-99
7646533-1	1995	Oxidation of the anticonvulsant drug milacemide [2-n-(pentylamino)acetamide] by monoamine oxidase-B (MAO-B) has been reported to be important in terminating its activity.	milacemide	37-47	monoamine oxidase B	Rattus norvegicus	101-106
7646533-1	1995	Oxidation of the anticonvulsant drug milacemide [2-n-(pentylamino)acetamide] by monoamine oxidase-B (MAO-B) has been reported to be important in terminating its activity.	milacemide	49-75	monoamine oxidase B	Rattus norvegicus	80-99
7646533-1	1995	Oxidation of the anticonvulsant drug milacemide [2-n-(pentylamino)acetamide] by monoamine oxidase-B (MAO-B) has been reported to be important in terminating its activity.	milacemide	49-75	monoamine oxidase B	Rattus norvegicus	101-106
7646533-3	1995	In keeping with this, the Ki values for milacemide acting as a competitive inhibitor of these enzymes showed it to have a lower affinity for ox liver MAO-B.	milacemide	40-50	monoamine oxidase B	Rattus norvegicus	150-155
8129740-5	1994	Milacemide was a reversible competitive inhibitor towards monoamine oxidase-A.	milacemide	0-10	monoamine oxidase A	Rattus norvegicus	58-77
8129740-7	1994	Determination of the formation of H2O2 and the aldehyde product of the oxidative cleavage of milacemide by purified monoamine oxidase-B from ox liver indicated that cleavage resulted solely in the formation of pentanal and glycinamide.	milacemide	93-103	monoamine oxidase B	Rattus norvegicus	116-135
8474100-0	1993	Inactivation of monoamine oxidase B by analogues of the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide).	milacemide	77-87	monoamine oxidase B	Homo sapiens	16-35
8216383-5	1993	The application of the procedure to assay the oxidation of benzylamine, tyramine and 2-n-pentylaminoacetamide (milacemide) by a crude mitochondrial preparation from rat liver and purified ox liver MAO-B is demonstrated.	milacemide	85-109	monoamine oxidase B	Rattus norvegicus	197-202
8216383-5	1993	The application of the procedure to assay the oxidation of benzylamine, tyramine and 2-n-pentylaminoacetamide (milacemide) by a crude mitochondrial preparation from rat liver and purified ox liver MAO-B is demonstrated.	milacemide	111-121	monoamine oxidase B	Rattus norvegicus	197-202
8512628-5	1993	Clinically significant increases in liver function tests, specifically aspartate aminotransferase and alanine aminotransferase (AST and ALT), were reported for five of the patients receiving milacemide, requiring their withdrawal from the study.	milacemide	191-201	glutamic--pyruvic transaminase	Homo sapiens	102-126
8512628-5	1993	Clinically significant increases in liver function tests, specifically aspartate aminotransferase and alanine aminotransferase (AST and ALT), were reported for five of the patients receiving milacemide, requiring their withdrawal from the study.	milacemide	191-201	solute carrier family 17 member 5	Homo sapiens	128-131
7931256-3	1994	An anticonvulsant prodrug, Milacemide [2-(N-pentyl)glycinamide] is deaminated by MAO-B and this facilitates a mechanism of delivering glycine into the CNS.	milacemide	27-37	monoamine oxidase B	Homo sapiens	81-86
8485621-7	1993	Pretreatment with L-deprenyl (2 mg kg-1), a specific inhibitor of monoamine oxidase type B (MAO-B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF.	milacemide	171-181	monoamine oxidase B	Rattus norvegicus	66-90
8485621-7	1993	Pretreatment with L-deprenyl (2 mg kg-1), a specific inhibitor of monoamine oxidase type B (MAO-B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF.	milacemide	171-181	monoamine oxidase B	Rattus norvegicus	92-97
8485621-19	1993	In conclusion, serum milacemide rapidly enters and equilibrates with the CNS compartment where it is metabolised primarily by MAO-B to glycinamide and finally to glycine.	milacemide	21-31	monoamine oxidase B	Rattus norvegicus	126-131
8474100-0	1993	Inactivation of monoamine oxidase B by analogues of the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide).	milacemide	89-115	monoamine oxidase B	Homo sapiens	16-35
8474100-1	1993	Analogues of the anticonvulsant agent milacemide (1,2-(n-pentylamino)acetamide), in which the carboxamide group is changed to a nitrile (2), a carbethoxy group (3), a carboxylic acid (4), a cyanomethyl group (5), and a trifluoromethyl group (6), were synthesized and tested as substrates and inactivators of monoamine oxidase B (MAO B).	milacemide	38-48	monoamine oxidase B	Homo sapiens	308-327
8474100-1	1993	Analogues of the anticonvulsant agent milacemide (1,2-(n-pentylamino)acetamide), in which the carboxamide group is changed to a nitrile (2), a carbethoxy group (3), a carboxylic acid (4), a cyanomethyl group (5), and a trifluoromethyl group (6), were synthesized and tested as substrates and inactivators of monoamine oxidase B (MAO B).	milacemide	38-48	monoamine oxidase B	Homo sapiens	329-334
1797336-3	1991	In vitro and in vivo studies, with numerous tissues, including adrenal chromaffin cells, have clearly shown that the formation of the latter metabolites is exclusively mediated by monoamine oxidase B for which milacemide is a substrate.	milacemide	210-220	monoamine oxidase B	Bos taurus	180-199
1632108-0	1992	Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat.	milacemide	68-78	polyamine oxidase	Rattus norvegicus	29-46
1632108-2	1992	It has previously been established that monoamine oxidase (MAO)-B participates in the metabolism of milacemide [2-(pentylamino)acetamide].	milacemide	100-110	monoamine oxidase B	Rattus norvegicus	40-65
1632108-2	1992	It has previously been established that monoamine oxidase (MAO)-B participates in the metabolism of milacemide [2-(pentylamino)acetamide].	milacemide	112-136	monoamine oxidase B	Rattus norvegicus	40-65
1632108-3	1992	Furthermore, in rats, inhibition of FAD-dependent polyamine oxidase (PAO) was found to decrease the urinary excretion of two milacemide metabolites, termed UK1 and UK2.	milacemide	125-135	polyamine oxidase	Rattus norvegicus	50-67
1632108-3	1992	Furthermore, in rats, inhibition of FAD-dependent polyamine oxidase (PAO) was found to decrease the urinary excretion of two milacemide metabolites, termed UK1 and UK2.	milacemide	125-135	polyamine oxidase	Rattus norvegicus	69-72
1632108-5	1992	Using gas chromatography-mass spectrometry, UK1 was identified as oxamic acid and UK2 as 2-hydroxyacetamide, confirming that PAO is involved in the metabolism of milacemide.	milacemide	162-172	polyamine oxidase	Rattus norvegicus	125-128
1632108-7	1992	Thus, two FAD-dependent amine-oxidizing enzymes, MAO and PAO, contribute to the metabolism of milacemide.	milacemide	94-104	monoamine oxidase A	Rattus norvegicus	49-52
1632108-7	1992	Thus, two FAD-dependent amine-oxidizing enzymes, MAO and PAO, contribute to the metabolism of milacemide.	milacemide	94-104	polyamine oxidase	Rattus norvegicus	57-60
1632108-8	1992	Milacemide appears to be the first non-polyamine xenobiotic in the metabolism of which PAO participates.	milacemide	0-10	polyamine oxidase	Rattus norvegicus	87-90
1596690-2	1992	Milacemide is a glycine prodrug which is both an inhibitor and a substrate for monoamine oxidase-type B (MAO-B) and also an inhibitor of MAO-type A (MAO-A).	milacemide	0-10	monoamine oxidase B	Rattus norvegicus	79-103
1596690-2	1992	Milacemide is a glycine prodrug which is both an inhibitor and a substrate for monoamine oxidase-type B (MAO-B) and also an inhibitor of MAO-type A (MAO-A).	milacemide	0-10	monoamine oxidase B	Rattus norvegicus	105-110
1596690-2	1992	Milacemide is a glycine prodrug which is both an inhibitor and a substrate for monoamine oxidase-type B (MAO-B) and also an inhibitor of MAO-type A (MAO-A).	milacemide	0-10	monoamine oxidase A	Rattus norvegicus	137-147
1596690-2	1992	Milacemide is a glycine prodrug which is both an inhibitor and a substrate for monoamine oxidase-type B (MAO-B) and also an inhibitor of MAO-type A (MAO-A).	milacemide	0-10	monoamine oxidase A	Rattus norvegicus	149-154
1596690-15	1992	The results are explicable in terms of an inhibition by milacemide of MAO-A.	milacemide	56-66	monoamine oxidase A	Rattus norvegicus	70-75
1634705-1	1992	OBJECTIVE: Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory.	milacemide	11-21	monoamine oxidase B	Homo sapiens	25-30
1797336-11	1991	The release of catecholamines from chromaffin cells in response to milacemide (10(-4) M) was partially inhibited by the selective MAO-B inhibitors (-)-deprenyl (10(-7) M) and AGN 1135 (10(-6) M).	milacemide	67-77	monoamine oxidase B	Bos taurus	130-135
1797336-12	1991	This indicates that the MAO-B derived metabolites, glycineamide and glycine, contribute to the secretion of catecholamines as does milacemide itself.	milacemide	131-141	monoamine oxidase B	Bos taurus	24-29
2089081-0	1990	MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice.	milacemide	56-66	monoamine oxidase A	Rattus norvegicus	0-3
2196964-5	1990	The same depressant effect was observed in animals pretreated with the monoamine oxidase B inhibitor (IMAO-B) deprenyl which is known to reduce milacemide metabolism into glycinamide and glycine.	milacemide	144-154	monoamine oxidase B	Homo sapiens	71-90
2043162-0	1991	Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?	milacemide	20-30	monoamine oxidase A	Mus musculus	34-53
2043162-1	1991	The anticonvulsant drug milacemide (2-n-pentylaminoacetamide) is known to be oxidized by monoamine oxidase-B to yield glycinamide which then breaks-down to give glycine.	milacemide	24-34	monoamine oxidase B	Mus musculus	89-108
2043162-1	1991	The anticonvulsant drug milacemide (2-n-pentylaminoacetamide) is known to be oxidized by monoamine oxidase-B to yield glycinamide which then breaks-down to give glycine.	milacemide	36-60	monoamine oxidase B	Mus musculus	89-108
2089081-1	1990	Milacemide was found to protect Swiss albino CD1 mice but not Sprague Dawley rats against bicuculline-induced lethality.	milacemide	0-10	CD1 antigen complex	Mus musculus	45-48
2089081-2	1990	Since it had been previously suggested that the anticonvulsant activity of milacemide might be related to MAO-B- mediated glycine formation, brain and liver MAO-A and-B activities and the urinary metabolic pattern of milacemide were determined in the same mice and rat strains.	milacemide	75-85	monoamine oxidase B	Mus musculus	106-111
2089081-2	1990	Since it had been previously suggested that the anticonvulsant activity of milacemide might be related to MAO-B- mediated glycine formation, brain and liver MAO-A and-B activities and the urinary metabolic pattern of milacemide were determined in the same mice and rat strains.	milacemide	75-85	monoamine oxidase A	Mus musculus	157-168
2128509-0	1990	Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?	milacemide	69-79	polyamine oxidase	Rattus norvegicus	19-36
2128509-1	1990	Milacemide, a secondary amine derivative, was previously demonstrated to be a substrate of MAO-B and to be insensitive to the action of copper-dependent amine oxidases.	milacemide	0-10	monoamine oxidase B	Rattus norvegicus	91-96
2128509-2	1990	In the present study, it was investigated whether the FAD-dependent secondary amine metabolizing enzyme polyamine oxidase (PAO), could participate in the metabolism of milacemide.	milacemide	168-178	polyamine oxidase	Rattus norvegicus	104-121
2128509-2	1990	In the present study, it was investigated whether the FAD-dependent secondary amine metabolizing enzyme polyamine oxidase (PAO), could participate in the metabolism of milacemide.	milacemide	168-178	polyamine oxidase	Rattus norvegicus	123-126
2128509-5	1990	The percent of the dose of milacemide eliminated as unchanged drug was slightly but significantly increased after PAO inhibition, though considerably less than after l-deprenyl.	milacemide	27-37	polyamine oxidase	Rattus norvegicus	114-117
2128509-6	1990	These data suggest that milacemide might be a substrate of PAO.	milacemide	24-34	polyamine oxidase	Rattus norvegicus	59-62
20504633-0	1990	Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey.	milacemide	0-10	monoamine oxidase B	Macaca mulatta	79-98
20504633-1	1990	Treatment of healthy male rhesus monkeys with milacemide 2(n-pentylaminoacetamide hydrochloride, 100 mg/kg, 21 days), the specific enzyme-activated inhibitor of monoamine oxidase B, resulted in a significant increase of dopamine (DA) in the caudate nucleus.	milacemide	46-56	monoamine oxidase B	Macaca mulatta	161-180
20504633-7	1990	The ability of milacemide to specifically inhibit MAO-B in the brain makes it a natural choice as adjuvant to l-dopa for the treatment of Parkinson"s disease.	milacemide	15-25	monoamine oxidase B	Macaca mulatta	50-55
2784529-5	1989	In vitro, milacemide inhibited both monoamine oxidase A and B from the frontal cortex of rats, to a greater extent for MAO B.	milacemide	10-20	monoamine oxidase A	Rattus norvegicus	36-61
2516327-4	1989	Prevention of the metabolism of milacemide to glycine by pretreatment with MAO-B inhibitors not only prevents the memory-enhancing effects of the drug, but appears to have a deleterious effect on memory formation suggesting an action of the prodrug itself on the brain.	milacemide	32-42	monoamine oxidase B	Rattus norvegicus	75-80
2769256-0	1989	The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.	milacemide	34-44	monoamine oxidase B	Homo sapiens	95-114
2769256-2	1989	Under the in vitro conditions used in the present study, milacemide acts as an enzyme-activated, partially reversible inhibitor of MAO-B.	milacemide	57-67	monoamine oxidase B	Homo sapiens	131-136
2769256-4	1989	The inhibitory activity of milacemide is significantly greater for MAO-B.	milacemide	27-37	monoamine oxidase B	Homo sapiens	67-72
2769256-6	1989	In contrast to the irreversible inhibitory action of L-deprenyl, the recovery of MAO-B activity in vivo after milacemide administration is significantly faster, a result suggesting that it is a partially reversible inhibitor.	milacemide	110-120	monoamine oxidase B	Homo sapiens	81-86
2769256-7	1989	The selective inhibitory effect of milacemide for MAO-B in vivo is confirmed by its potentiation of phenylethylamine-induced stereotyped behavior, whereas vasopressor responses to tyramine were not affected.	milacemide	35-45	monoamine oxidase B	Homo sapiens	50-55
2784529-5	1989	In vitro, milacemide inhibited both monoamine oxidase A and B from the frontal cortex of rats, to a greater extent for MAO B.	milacemide	10-20	monoamine oxidase B	Rattus norvegicus	119-124
2568664-2	1989	It is now apparent that MAO-B is capable of oxidizing inert non-polar amines such as MPTP (N-methyl-4-phenyl-1,2,3,6, tetrahydropyridine) and milacemide (2-n-pentylaminoacetamide) into neuroactive substances giving rise to Parkinson inducing dopaminergic neurotoxin, MPP+ and inhibitory amino acid neurotransmitter, glycine respectively.	milacemide	142-152	monoamine oxidase B	Homo sapiens	24-29
2568664-2	1989	It is now apparent that MAO-B is capable of oxidizing inert non-polar amines such as MPTP (N-methyl-4-phenyl-1,2,3,6, tetrahydropyridine) and milacemide (2-n-pentylaminoacetamide) into neuroactive substances giving rise to Parkinson inducing dopaminergic neurotoxin, MPP+ and inhibitory amino acid neurotransmitter, glycine respectively.	milacemide	154-178	monoamine oxidase B	Homo sapiens	24-29
6414480-9	1983	On the other hand, the glutamate decarboxylase activity measured ex vivo 3 hr after 100 mg/kg of milacemide is significantly increased by 11% in homogenates of the whole rat brain.	milacemide	97-107	glutamate-ammonia ligase	Rattus norvegicus	23-46
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	35-45	monoamine oxidase B	Homo sapiens	73-78
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	35-45	monoamine oxidase A	Homo sapiens	167-172
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	129-139	monoamine oxidase B	Homo sapiens	73-78
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	129-139	monoamine oxidase A	Homo sapiens	167-172
3346666-5	1988	In vitro MAO-B (l-deprenyl and AGN 1135) rather than MAO-A (clorgyline) selectively inhibited the oxidation of milacemide.	milacemide	111-121	monoamine oxidase B	Homo sapiens	9-14
3346666-9	1988	The present data therefore demonstrate that milacemide is a substrate for brain MAO-B, and its conversion to glycinamide, further transformed to the inhibitory neurotransmitter, glycine, mediated by this enzyme may contribute to its pharmacological activities.	milacemide	44-54	monoamine oxidase B	Homo sapiens	80-85
3138141-4	1988	These results suggest that, in the brain, milacemide is oxidized to glycine and that this reaction is mediated primarily by monoamine oxidase B.	milacemide	42-52	monoamine oxidase B	Homo sapiens	124-143
3346666-0	1988	Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.	milacemide	66-76	monoamine oxidase B	Homo sapiens	98-117